Overview of salt restriction in the Dietary Approaches to Stop Hypertension (DASH) and the Mediterranean diet for blood pressure reduction

Christina Filippou¹, Fotis Tatakis¹, Dimitrios Polyzos¹, Eleni Manta¹, Costas Thomopoulos², Petros Nihoyannopoulos¹, Dimitrios Tousoulis¹, Konstantinos Tsiofis¹,*

¹First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece
²Department of Cardiology, Helena Venizelou Hospital, 11521 Athens, Greece
*Correspondence: ktsiofis@hippocratio.gr (Konstantinos Tsiofis)

Abstract

Despite considerable advances in pharmacological treatments, hypertension remains a major cause of premature morbidity and mortality worldwide since elevated blood pressure (BP) adversely influences cardiovascular and renal outcomes. Accordingly, the current hypertension guidelines recommend the adoption of dietary modifications in all subjects with suboptimal BP levels. These modifications include salt intake reduction and a healthy diet, such as the Dietary Approaches to Stop Hypertension (DASH) diet or the Mediterranean diet (MedDiet), independently of the underlying antihypertensive drug treatment. However, dietary modifications for BP reduction in adults with prehypertension or hypertension are usually examined as stand-alone interventions and, to a lesser extent, in combination with other dietary changes. The purpose of the present review was to summarize the evidence regarding the BP effect of salt restriction in the context of the DASH diet and the MedDiet. We also summarize the literature regarding the effects of these dietary modifications when they are applied as the only intervention for BP reduction in adults with and without hypertension and the potent physiological mechanisms underlying their beneficial effects on BP levels. Available data of randomized controlled trials (RCTs) provided evidence about the significant BP-lowering effect of each one of these dietary strategies, especially among subjects with hypertension since they modulate various physiological mechanisms controlling BP. Salt reduction by 2.3 g per day in the DASH diet produces less than half of the effect on systolic blood pressure (SBP)/diastolic blood pressure (DBP) (−3.0/−1.6 mmHg) as it does without the DASH diet (−6.7/−3.5 mmHg). Although their combined effect is not fully additive, low sodium intake and the DASH diet produce higher SBP/DBP reduction (−8.9/−4.5 mmHg) than each of these dietary regimens alone. It is yet unsettled whether this finding is also true for salt reduction in the MedDiet.

Keywords: Salt; Sodium; Dietary approaches to stop hypertension; DASH; Mediterranean diet; Blood pressure; Hypertension; Review

1. Stating the problem

Elevated blood pressure (BP) is the leading modifiable risk factor contributing to the global burden of cardiovascular disease (CVD) [1]. To date, the number of adults with hypertension has doubled worldwide since 1990, reaching 2019 1.28 billion adults, meaning that the global age-standardized prevalence rate of hypertension is on average 32% for women and 34% for men [2]. Cardiovascular causes principally drive the number of deaths due to high BP, but chronic kidney disease (CKD) also remains an important contributor. An estimated 7.7–10.4 million annual deaths from ischemic heart disease, stroke, and CKD are attributable to systolic blood pressure (SBP) levels higher than 115 mmHg [3]. When BP is reduced within goal among patients with hypertension, it is accompanied by a significant reduction in fatal and non-fatal outcomes [4].

The pathophysiological mechanisms of hypertension are rather complex. The “mosaic theory” hypothesized that abnormal BP stems from altered regulatory systems involving cardiovascular, renal, neuroendocrine, and inflammatory pathways. The overall cardiovascular homeostasis is also influenced by multiple genetic and environmental factors [5]. Visceral obesity and ectopic fat storage in organs and tissues controlling cardiovascular function (heart, blood vessels and, kidneys) appear to be a pivotal component in the pathogenesis of hypertension since both systolic and diastolic functions are being impaired [6]. Among dietary factors, excessive sodium consumption is a major contributor to the development of hypertension, and sodium restriction has been regarded as a popular recommendation for BP reduction, which is being included in lifestyle modification, irrespectively of BP levels [7].

In the last decades, a substantial number of interventional and observational studies investigated the relationship between dietary sodium intake and BP levels. As a result, mounting evidence supports a direct association between sodium intake and BP increase [8]. However, sodium restriction as a measure to promote BP reduction has usu-
ally been examined in randomized controlled trials (RCTs) separately from other interventions and less likely in combination with other lifestyle changes, such as weight loss, physical exercise, or adoption of a specific dietary pattern [9,10]. Examples of dietary patterns that have been recognized as effective dietary interventions to reduce BP are the Dietary Approaches to Stop Hypertension (DASH) diet and the Mediterranean diet (MedDiet) [11,12]. However, the contribution of salt restriction under and above these dietary patterns on BP reduction remains by and large unclear.

In the present review, we summarized the available evidence from RCTs for the BP effects of salt restriction in the context of the DASH diet and the MedDiet. First, we focused on studies examining the BP effects of salt restriction when it is applied as the only intervention for BP reduction in adults with and without hypertension. Second, we reported the literature summary regarding the BP effect of the DASH and the MedDiet in subjects with or without hypertension, without a concomitant salt restriction. Finally, we considered the BP-lowering effect of salt restriction in the context of the DASH and the MedDiet. In each section, we presented evidence from RCTs to avoid methodological bias of observational studies. To select eligible meta-analyses of RCTs, we performed a literature search in PubMed, combining appropriate keywords for each examined dietary strategy. The filter “Meta-Analysis” was activated. In addition, references of the retrieved meta-analyses were searched to identify any missing meta-analyses.

2. The interplay between sodium intake and blood pressure

Salt is necessary for human health, consisting mainly of sodium chloride (NaCl) [13]. One sodium chloride molecule represents a 1:1 sodium (Na\(^+\)) and chloride (Cl\(^-\)) ions ratio. However, chloride contributes more than sodium to the molecule’s weight, and one gram of sodium chloride provides 0.4 g of sodium and 0.6 g of chloride [14]. Thus, one of these two elements’ main functions lies in the homeostatic control of the extracellular fluid volume, strictly regulated by mechanisms triggered by sodium and chloride concentrations changes. Thereby, salt intake, through the concomitant provision of sodium and chloride, is involved in regulating total body water, blood volume, and by extension, the level of BP values [15,16].

The gastrointestinal tract absorbs almost entirely dietary salt, and the kidneys retain more than 90% of the filtered sodium [17]. Therefore, sodium handling became one of the kidneys’ main physiologic functions, because, for several million years, people in Prehistoric times consumed a diet naturally low in sodium, with less than 1 g of salt per day [18]. However, nowadays, this sodium conservation mechanism may not be beneficial since people consume through their diets almost 10 times higher sodium than what is deemed physiologically necessary [19]. The proposed physiologically necessary sodium amount is less than 500 mg per day (i.e., less than 1.25 g of salt per day) [20]. The food industry’s abundance of salty processed foods is mainly responsible for the high dietary salt intake, estimated at 9–12 g per day in most countries. However, there are marked differences between countries and regions within countries [21]. Furthermore, this increase in salt intake took place in a short period in the evolutionary timescale. As a result, kidneys programmed for a low salt diet may at some time fail to excrete chronic excessive salt intake and contribute to the elevation of BP levels [22].

Excessive sodium consumption (i.e., more than 5000 mg sodium or 12.5 grams of salt per day) is an important risk factor for hypertension [23]. Indeed, it increases BP by (1) a volume-dependent mechanism due to plasma expansion [24] and (2) a volume-independent mechanism due to the activation of the renin-angiotensin-aldosterone system (RAAS) [25] and the sympathetic nervous system (SNS) [26]. Also, increased sodium intake is associated with endothelial dysfunction [27] and peripheral vascular resistance increments [28]. These pathophysiological mechanisms linking excessive salt consumption with hypertension have been extensively reviewed. Regarding volume-dependent mechanisms, the osmolality of extracellular fluid increases since ingested sodium is confined mainly to the extracellular space [29]. In an attempt to excrete excess sodium and restore osmolarity, the body enhances the action of anti-diuretic hormone. It also inhibits the action of aldosterone at the kidney level, resulting in a decrease in the amount of urine excreted and an increase in their sodium concentration [30]. These mechanisms restore osmolarity at the expense of water retention, extracellular fluid volume expansion, and increased cardiac output [31]. Subsequently, different mechanisms are activated, such as pressure natriuresis and diuresis [32,33]. High salt and water excretion are accomplished through the increased intraglomerular pressure until the blood volume is sufficiently reduced and BP levels are lowered [34,35].

However, BP levels are not changing predictably for all individuals [36]. In some people, the so-called salt-sensitive, PB exhibits changes parallel to the changes in salt intake [37]. The pathophysiological mechanisms of underlying salt-sensitivity remain elusive. However, they may be influenced by genetic to environmental factors and seem associated with older age, black race, CKD, obesity, and metabolic syndrome [38,39]. Salt-sensitive individuals cannot excrete increased dietary salt amounts, and BP elevation is a regulatory mechanism to address sodium overload effectively [40]. Suppose a salt-sensitive individual consumes for prolonged time intervals excessive salt. In that case, the kidneys are constantly “forced” to excrete large amounts of sodium until their excretory ability is deteriorated [41], and hypertension develops to produce sufficient excretion of sodium and water [42,43]. The latter is mediated by resetting the pressure-sodium excretion curve,
### 3. To what extent should sodium intake be lowered?

According to the 2012 World Health Organization’s (WHO) recommendations, in adults over 16 years, sodium intake should be reduced to less than 2000 mg per day (equivalent to <5 g salt per day) [45]. Furthermore, the 2018 European Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines for the management of arterial hypertension also recommend sodium intake to be limited to approximately to 2000 mg per day in the general population and to try to achieve this goal in all hypertensive patients [46]. In addition, the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the prevention and management of high BP in adults propose to reduce sodium intake to <1500 mg per day (equivalent to <3.75 g salt per day) [47]. These guidelines about sodium intake concern both patients with hypertension and normotensive individuals.

The effect of dietary salt on BP levels was first noted in 1904 in France by Ambard and Beaujard, who studied 6 patients with high BP for 3 weeks and observed that when the dietary salt was decreased, BP fell, while the increase in salt intake had the opposite effect and BP rose [48]. In the early 1920s, Allen and Sherrill in the United States confirmed this finding [49]. Kempner offered confirmatory findings in 1948, who used a rice diet with less than 0.5 g salt per day in 500 patients with severe hypertension and showed that this rice diet with strict salt restriction could produce remarkably lower BP levels [50]. Subsequently, beginning in the 1970s, the effect of moderate salt restriction in patients with less severe hypertension or normotensive adults was studied in experimental trials. The first double-blind controlled study providing evidence about the BP-lowering effect of moderate salt restriction in patients with mild to moderate hypertension was conducted in 1982 by MacGregor et al. [51], followed by subsequent research in the field.

Dietary interventions mostly compare low sodium intake to usual or high sodium intake in the context of the habitual diet either by dietary modification (e.g., counseling to reduce salt during cooking and at the table and to avoid highly salty processed foods) or by supplementation with sodium or placebo tablets. However, the definitions of “low”, “usual”, and “high” sodium intake are unclear, and consequently, these terms indicate different ranges of sodium intake. Generally, and according to health institutions’ recommendations, low sodium intake is below 2000 mg per day, usual sodium intake is between 2000 and 5000 mg per day, and high sodium intake is above 5000 mg per day. Through the years, several meta-analyses of RCTs have also been conducted to estimate the effect of a salt-restricted diet compared to the control diet on BP reduction. The most recent update of meta-analytical approaches is presented in Table 1 (Ref. [52–60]).

Almost all meta-analyses provided evidence about the significant lowering effect of sodium reduction on BP, ranging from –2.5 (95% CI: –3.8 to –1.2) to –4.8 (95% CI: –3.9 to –5.7) mmHg, regarding SBP and from –1.2 (95% CI: –1.8 to –0.7) to –2.1 (95% CI: –2.7 to –1.5) mmHg, regarding diastolic blood pressure (DBP) [52–57,59,60], for a median sodium reduction ranging from –1.13 (range: –1.50 to –0.74) to –2.30 (range: –7.54 to –0.46) g per day [52–55,57,60]. All meta-analyses agreed that for the same reduction in salt intake BP reduction was greater in patients with hypertension compared to individuals without hypertension. In hypertensive patients SBP/DBP reduction ranged from –4.1 (95% CI: –5.1 to –2.9) to –8.0 (95% CI: –15.7 to –0.3)/–2.3 (95% CI: –3.0 to –1.5) to –4.3 (95% CI: –7.1 to –1.6) mmHg, while in normotensive individuals SBP/DBP reduction ranged from –1.1 (95% CI: –1.7 to –0.6) to –2.4 (95% CI: –3.6 to –1.3)/0.0 (95% CI: –0.4 to 0.4) to –1.2 (95% CI: –1.8 to –0.6) mmHg [52–58].

The main differential component that distinguishes the presented meta-analyses is the duration of the included trials, i.e., some meta-analyses included salt restriction trials of less than one week, while others excluded short-duration trials. The modification effect of trial duration for the impact of salt reduction on BP is challenging and yet unclear. Indeed, the inclusion of salt restriction trials of less than one week produced significant BP-lowering in hypertension and a trivial effect in normotensive individuals [52,58]. It has also been suggested that the effect of a sustained salt restriction on BP levels is not different after the first week from baseline [58,61,62]. Thus, the indifferent BP-lowering effect following salt restriction in normotensive individuals is potentially related to differential activation of neuro-hormonal factors compared to patients with hypertension [58]. However, in additional meta-analyses, the exclusion of short-duration trials was associated with a significant BP-lowering effect independently of hypertension status [53–57,60].

In a step further, Graudal et al. [58], in their meta-analysis, studied the effect of reducing dietary sodium from about 4700 to about 1500 mg per day, i.e., from a level corresponding to the present usual intake of the world’s populations to a low level following the recommendations of the health institutions. The authors concluded that white normotensives do not benefit from sodium reduction but may experience potential harm due to the adverse effects on hormones and lipids. In contrast, white hypertensives may benefit from BP-lowering but may also be exposed to potential harms. Therefore, since sodium reduction does not have net beneficial effects in a population of white people with normal BP, a small BP-lowering does not justify the recommendation for sodium reduction in the general population [58].

Overall, the conflicting findings of the above meta-analyses question the current recommendations to reduce salt intake from 9–12 to 5–6 g per day. Thus, the question
regarding the optimum level of sodium intake is still controversial. Indeed, the meta-analysis by Graudal et al. [58] about the absence of public health benefits when sodium is reduced in non-hypertensive individuals is driven by the results from the very short-term trials in which time-limited and large reductions in salt intake were pursued. By contrast, modest and long-term reduction in salt intake can have important public health benefits, since even a relatively small BP-lowering effect of decreased sodium intake across the entire population, including the subjects without high BP, may contribute to CVD reduction [53–57,60].

Regarding the adverse effects of sodium reduction on hormones and blood lipids, Aburto et al. [56] showed that reducing sodium intake for at least one month had no impact on catecholamine levels or blood lipids. Authors raised the hypothesis that metabolic changes occurring after large and rapid reductions in salt intake do not occur with moderate and sustained salt reduction. Also, He, et al. [57] stated that the compensatory mechanisms involving the activation of the RAAS and the SNS are more extensive with sudden and large decreases in salt intake. Huang et al. [59] included in their meta-analysis trials regardless of the length of the intervention duration to examine its effect on the studied outcomes. They found that the duration of the sodium reduction intervention was not associated with the magnitude of either SBP or DBP reduction. However, they identified in studies of longer than two weeks’ duration an approximately twice as large effect of sodium reduction on BP compared with short-term studies of less than 15 days’ duration. The authors suggested that (1) the short-term responses of the RAAS and the SNS, and (2) the unfavorable metabolic effects associated with extreme falls in dietary sodium are not sustained in longer-term interventions and do not outweigh the long-term benefits anticipated from BP-lowering.

The dose-response relationship between the reduction in salt intake and the magnitude of BP-lowering has also been demonstrated, i.e., the greater the reduction in salt intake, the greater the fall in BP levels [52,53,57,59,60]. In the largest meta-analysis of RCTs [60], an almost linear relationship was identified between attained sodium intake and BP levels with no flattening of the curve or a threshold for the effect of sodium reduction on BP across the entire range of dietary sodium exposure (0 to 6900 mg per day of sodium excretion). However, the curve for SBP was steeper than for DBP. In linear regression analysis, every 2300 mg per day reduction in urinary sodium excretion was associated with a lower mean SBP of –5.6 mmHg (95% CI: –4.5 to –6.6) and a lower mean DBP of –2.3 mmHg (95% CI: –1.7 to –3.0). The roughly linear association between the achieved sodium intake and BP change was observed in hypertensive patients and individuals without hypertension. However, after sodium reduction, participants with hypertension than normotension showed a steeper decrease in BP. The only exception were participants without hypertension whose sodium intake was <2 g per day, for whom there was little evidence regarding the BP effect of sodium reduction. Moreover, a higher baseline sodium intake (<2.5 g versus ≥ 2.5 g per day) resulted in greater BP-lowering at a given change in sodium intake. Thus, reducing sodium consumption has a greater capacity to lower BP in high sodium consumers [60].

4. DASH diet and blood pressure reduction

The DASH diet is a dietary pattern that emphasizes the consumption of fruits, vegetables, and low-fat dairy products, including whole grains, legumes, nuts, fish, and poultry while containing decreased amounts of fat, red meat, and sweets/sugar-containing beverages. Also, the DASH diet is naturally low in sodium [63]. The high content in potassium, calcium, magnesium, and fiber, along with the reduced-sodium, trans/saturated/total fat, and dietary cholesterol content, are considered the beneficial components of the DASH diet [64]. The various effects of the dietary patterns are linked to the synergistic effects produced by the combination of foods and nutrients being habitually consumed in their context [65]. Although the DASH diet is widely recognized as an effective dietary intervention to reduce BP, the mechanisms exerting its antihypertensive effect are not fully known. However, several potential physiological effects of the DASH diet have been proposed and correlated to BP reduction [66].

Particularly, the DASH diet seems to interact with the RAAS, enhancing some of the physiologic effects of angiotensin-converting enzyme (ACE) inhibition and resulting in a natriuretic and diuretic effect [67]. Regarding the DASH diet effect on the pressure-natriuresis curve (arterial BP-urinary sodium output relationship), the slope of the pressure-natriuresis curve is increased without shifting the curve along the BP axis. Accordingly, the DASH diet acts as a diuretic, enhancing the salt output at each BP level. For this reason, the DASH diet has a greater BP-lowering effect in salt-sensitive individuals whose slopes are depressed [68]. The natriuretic action of the DASH diet has been mainly attributed to its high content in potassium and calcium, coming from its high content in fruits, vegetables, and low-fat dairy products. Potassium is known for its role in regulating BP, and its natriuretic action [69], while calcium has also been shown to blunt the pressure effects of dietary sodium [70]. Other important nutrients of the DASH diet are numerous vitamins, phytochemicals, and antioxidants, such as polyphenols and especially flavonoids, which attenuate oxidative stress. Moreover, it has been found that they inhibit or decrease inflammation through the lowering of high-sensitivity C-reactive protein (hs-CRP) and reduce subclinical cardiac injury through the lowering of high-sensitivity cardiac troponin I (hs-cTnI) [71]. Also, the consumption of fruits and vegetables rich in inorganic nitrate improves endothelial function, reduces arterial stiffness, and decreases platelet aggregation through nitric oxide-related mechanisms because nitrate can be
### Table 1. Effect of salt reduction on BP: results from published meta-analyses of RCTs examining the effect of salt reduction on SBP and DBP in adults.

| Author, et al., year | Studies, Participants, n | Duration of trials | BP difference (mmHg) | Sodium intake (mg per day) |
|----------------------|--------------------------|--------------------|----------------------|---------------------------|
|                      |                          | Median (range)     | SBP                  | DBP                       | Change during intervention |
|                      |                          |                    |                     |                           |                           |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | All subjects       | Patients with hypertension | Normotensive individuals |                          |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |
|                      |                          | Patients with hypertension | Normotensive individuals |                          |                           |
|                      |                          | Mean (95% CI)      | Mean (95% CI)        | Median (range)            |                          |

BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; NR, not reported; RCT, randomized controlled trial; SBP, systolic blood pressure. *Mean ± SD, **Mean (SD), ***Mean (95% CI).
metabolized to nitric oxide [72]. Collectively, these data suggest that the DASH diet induces hormonal and vascular responses related to its hypotensive effect and additional responses in end-diastolic volume and stroke volume related to its beneficial effect on left ventricular function [73].

The 2017 ACC/AHA guidelines for preventing and managing high BP in adults recommend a heart-healthy diet, such as the DASH diet, for adults with elevated BP. The 2020 International Society of Hypertension (ISH) global hypertension practice guidelines also recommend preventing or delaying high BP by eating a diet like the DASH. In addition, these guidelines highlighted the increased intake of vegetables high in nitrates known to reduce BP, such as leafy vegetables and beetroot [74].

The BP-lowering effect of the DASH diet was first noted almost 25 years ago, when the initial DASH clinical trial, which was a controlled feeding trial, tested the effects of 3 different diets on BP levels in adults with stage 1 hypertension and without hypertension. The “combination” diet, which was rich in fruits, vegetables, and low-fat dairy products, currently named the “DASH” diet, reduced SBP/DBP compared to the control diet by –5.5 (95% CI: –7.4 to –3.7)/–3.0 (95% CI: –4.3 to –1.6) mmHg and compared to the fruits-and-vegetables diets by –2.7 (95% CI: –4.6 to –0.9)/–1.9 (95% CI: –3.3 to –0.6) mmHg. The salient BP reduction between diets suggests that (1) some components of the fruits-and-vegetables diet, and (2) additional components of the “combination” (DASH) diet may synergistically contribute to BP-lowering. The results were even more pronounced among subjects with stage 1 hypertension, in whom compared to the control diet, SBP/DBP was reduced by –11.4 (95% CI: –15.9 to –6.9)/–5.5 (95% CI: –8.2 to –2.7) mmHg [75].

This study demonstrated that the effects of the original DASH diet on BP occurred without energy or sodium restriction since bodyweight was kept constant and the sodium content of each diet was similar (approximately 3000 mg per day). Given the body of evidence regarding the BP-lowering effect of salt restriction, the DASH trial research group subsequently conducted a second controlled feeding trial to determine the BP effects of sodium restriction alone and in combination with the DASH diet. Specifically, the DASH-Sodium trial investigated among adults with stage 1 hypertension and without hypertension the extent to which reducing sodium intake at 3 different sodium levels lowers BP within the context of the DASH and the control diet. The participants were randomly assigned to the control or the DASH diet. They were fed for 30 consecutive days on their assigned diet in a crossover design with 3 different sodium levels: low, intermediate, and high (1150, 2300, and 3450 mg, respectively, at 2100 kcal). The high level reflected the average sodium intake in the United States. The medium level corresponded to prevailing sodium recommendations, whereas the lower level represented a level that might further lower BP [76].

Confirming the results by Appel et al. [75], the DASH-Sodium trial showed that the DASH diet significantly reduced BP than the control diet. Extending the previous results, it was found that this was true for SBP at every sodium level, i.e., at the high [–5.9 (95% CI: –8.0 to –3.7) mmHg], the intermediate [–5.0 (95% CI: –7.6 to –2.5) mmHg] and the low level [–2.2 (95% CI: –4.4 to –0.1) mmHg] and for DBP only at the high [–2.9 (95% CI: –4.3 to –1.5) mmHg] and the intermediate level [–2.5 (95% CI: –4.1 to –0.8) mmHg]. Compared to the control diet, the effect of the DASH diet on both SBP and DBP was larger at the high than at the intermediate and the low sodium levels. This study also showed that in the context of the control diet, the reduction of sodium intake lowered SBP/DBP significantly in a stepwise manner from the high to the intermediate [–2.1 (95% CI: –3.4 to –0.8)/–1 (95% CI: –1.9 to –0.2) mmHg] and from the intermediate to the low level of sodium [–4.6 (95% CI: –5.9 to –3.2)/–2.4 (95% CI: –3.3 to –1.5) mmHg]. Notably, going from the intermediate to the low sodium intake level, the effects on SBP and DBP were greater. In the context of the DASH diet, sodium reduction reduced SBP from the high to the intermediate [–1.3 (95% CI: –2.6 to 0.0) mmHg] and from the intermediate to the low level of sodium intake [–1.7 (95% CI: –3.0 to –0.4) mmHg], but DBP was reduced only from the intermediate to the low level of sodium intake [–1.0 (95% CI: –1.9 to –0.1) mmHg]. An almost similar pattern as in the control diet was observed. However, the progressive reduction in sodium intake from the high to the low level had an almost double effect on SBP/DBP in the context of the control [–6.7 (95% CI: –5.4 to –8.0)/–3.5 (95% CI: –2.6 to –4.3) mmHg], as it did in the context of the DASH diet [–3.0 (95% CI: –1.7 to –4.3)/–1.6 (95% CI: –0.8 to –2.5) mmHg] [76].

Finally, the greatest benefit on BP was observed when the low sodium intake was coupled with the DASH diet, especially among subjects with hypertension. In a secondary analysis of the DASH-Sodium trial, according to baseline levels of SBP, compared to the control diet with high sodium, the DASH diet with low sodium lowered SBP by –9.7 (95% CI: –13.3 to –6.6) mmHg among those with a baseline SBP of 140 to 149 mmHg and by –20.8 (95% CI: –30.9 to –10.7) mmHg among those with a baseline SBP ≥150 mmHg. Thus, although the combined effects on BP of low sodium intake and the DASH diet were greater than the effects of either intervention alone, they were not as great as they would have been if the effects of each dietary intervention were strictly additive [76,77].

The less pronounced effects of sodium reduction in the context of the DASH compared to the control diet may occur because of the already low BP resulting from each of these dietary regimens. Sacks et al. [76] assumed that low amounts of dietary sodium attenuated the hypotensive effects of potassium in the DASH diet or, inversely, the
high potassium or calcium content of the DASH diet attenuated the effects of low amounts of sodium. The lack of an additive effect resulting from low sodium intake and the DASH diet could be explained by considering the data of the pressure-natriuresis relationship mentioned earlier. Since the DASH diet increases the slope of the pressure-natriuresis curve, as if it was a diuretic, it is assumed that it lowers BP effectively in subjects with high sodium sensitivity by making BP less sodium-sensitive. For this reason, the BP-lowering effect of sodium restriction may be attenuated in the context of the DASH compared to the control diet. By extension, their combined effect is smaller rather than fully additive. Also, it is of note that the pressure-natriuresis curves suggest that the effect of the DASH diet on BP would be diminished at very low sodium intakes, e.g., 500 or 700 mg per day [68].

The DASH and the DASH-Sodium trials provided strong evidence that both the DASH diet and sodium restriction, alone or together, significantly reduce BP. These two clinical trials have been extensively discussed and reviewed and, in the meanwhile, numerous subsequent RCTs confirmed these findings. However, the DASH diet was often examined alone and to a lesser extent in combination with sodium restriction. Through the past years, several meta-analyses of RCTs have also been conducted to estimate the effect of the DASH diet compared to the control diet on BP reduction, with or without concomitant sodium reduction, which are presented in Table 2 (Ref. [11,78–82]). In the meta-analysis conducted recently by our group [11], we moved on a step further. We examined the modification effect of salt intake on BP reduction in the context of the DASH diet. We performed a subgroup analysis according to daily sodium intake and compared the results to the DASH-Sodium clinical trial.

All these meta-analyses of RCTs investigating the effect of the DASH diet on BP demonstrated that the DASH diet significantly reduced both SBP and DBP and confirmed its effectiveness as a nutritional strategy for the prevention and management of hypertension [11,78–82]. However, except for the meta-analysis conducted recently by our group [11], BP estimates presented the absolute mean BP difference as a change from baseline BP [78–82]. Consequently, the reported BP reduction, ranging from −3.9 (95% CI: −5.2 to −2.6) to −7.6 (95% CI: −9.9 to −5.3) mmHg, regarding SBP and from −2.4 (95% CI: −3.4 to −1.5) to −4.2 (95% CI: −5.9 to −2.6) mmHg, regarding DBP, introduced outcome-related bias. At variance with the previous evidence, we considered the attained mean SBP/DBP difference between the two randomized arms during follow-up. We found that it was −3.2 (95% CI: −4.2 to −2.3) and −2.5 (95% CI: −3.5 to −1.5) mmHg for SBP and DBP, respectively [11]. Considering hypertension status, three of these meta-analyses found that the BP-lowering effect of the DASH diet was greater among individuals with hypertension compared to those without hypertension [78,79,81].

We observed no differential SBP/DBP-lowering between the two randomized arms according to hypertension status. The underlying “regression to the mean” phenomenon or different operating pathophysiological pathways in hypertension, such as endothelial dysfunction and increased sympathetic tone, may limit but not neutralize the BP-lowering effect of the DASH diet [11].

Regarding the influence of sodium intake on BP in the context of the DASH diet, two of the meta-analyses mentioned above also reported meta-regression analyses for the relationship between the difference in dietary sodium intake and the attained BP levels [78,79]. Saneei et al. [78] found that the difference in sodium intake between the intervention and the control groups was significantly associated with the fall in SBP but not in DBP. On the other hand, Siri et al. [79] reported that both SBP and DBP changes were independent of the differences in dietary sodium intake. Therefore, the authors stated that the lack of a significant association between dietary sodium intake and BP was not anticipated. This phenomenon might be due to the differences between the trials concerning dietary sodium intake in both the DASH and the control groups, the assessment of sodium intake (dietary intake or 24-h urinary excretion assessment), and the type of the dietary intervention (controlled feeding study or provision of dietary advice).

In the meta-analysis conducted by our group, the univariate meta-regression analysis of change in 24-h urinary sodium excretion during follow-up revealed that it had no significant modifying effect on SBP or DBP reduction. However, the subgroup analysis conducted according to daily sodium intake showed that the treatment effect of the DASH diet was more pronounced regarding SBP reduction in trials with sodium intake >2400 mg per day compared to trials with sodium intake ≤2400 mg per day. The graphical displays of the estimated SBP results from the included studies according to sodium intake are presented in the forest plots of Fig. 1. These findings agree with the results of the DASH-Sodium trial, proving that higher levels of daily sodium intake enhance the BP-lowering effect of the DASH diet [11].

5. Mediterranean diet and blood pressure reduction

The MedDiet is a dietary pattern that emphasizes whole grains, fruits, vegetables, legumes, and nuts. It is characterized by increased total fat consumption, with olive oil being the principal source of added fat. It also includes fish and seafood, low-fat dairy products, poultry, and eggs and contains decreased amounts of red meat and sweets/sugar-containing beverages. Finally, moderate consumption of alcohol, mainly red wine during meals, is present in the MedDiet [83]. The high content in antioxidants and anti-inflammatory nutrients, fibers, ω-3 poly- and mono-unsaturated fat, the moderate content in ethanol, and the low content in trans/saturated fat and dietary cholesterol...
Fig. 1. Blood pressure-lowering effect of the DASH diet in adults with and without hypertension: Subgroup analysis of trials for SBP outcome, according to daily sodium intake. CI, confidence interval; DASH, dietary approaches to stop hypertension; NA, not applicable; SBP, systolic blood pressure. Difference in means of the attained SBP difference in trials with sodium intake ≤2400 mg per day (left forest plot) and in trials with sodium intake >2400 mg per day (right forest plot) for the effect of the DASH diet compared to control diet. In each subgroup of trials, from left to right, the columns indicate first author, year, the number of subjects in the two randomized arms, the difference in mean and 95% CIs for SBP outcome (the minus sign indicates a lower BP value in the first group), and the forest plot of the difference in means and 95% CIs. Blood pressure in mmHg.

are considered the beneficial components of the MedDiet diet [84]. The synergetic action of these components attenuates the intermediate CVD pathways of atherosclerosis and thrombosis since they exert a protective effect on endothelial function by mitigating the processes of oxidative stress and inflammation [85]. Moreover, the components of the MedDiet improve multiple CVD risk factors, including elevated BP levels, although the way the MedDiet induces BP changes is not fully understood [86]. It seems that olive oil might be the component of the MedDiet with a favorable effect on BP. First, the high content in mono-unsaturated fatty acids, vitamin E, and polyphenols, especially flavonoids, may increase nitric oxide availability, promote vasodilation, and improve endothelial function [87]. Second, fruits and vegetables, which are rich in (1) vitamins (e.g., vitamin C), (2) minerals (e.g., potassium), (3) fibers, (4) numerous bioactive compounds (e.g., like phytosterols, inorganic nitrate), and (5) phytochemicals (i.e., polyphenols-flavonoids) may contribute to endothelium-dependent vasodilation and inhibition of platelet aggregation [88]. Third, regarding whole grains, the potential beneficial effects on BP may be associated with the high dietary fiber content and minerals highly linked to fiber intake [89]. Last, red wine is a complex blend of ingredients, such as polyphenols (including resveratrol), having a positive biological effect on the cardiovascular system since they exert antioxidant and anti-inflammatory effects [90].

The 2018 ESC/ESH guidelines for hypertension management recommend that hypertensive patients should be advised to eat a healthy, balanced diet, such as the MedDiet [46]. Also, the 2021 ESC Guidelines for CVD prevention recommend adopting a MedDiet or a similar diet to lower CVD risk. Specifically, it is recommended to choose a more plant- and less animal-based food pattern [91].

The very first evidence about the cardioprotective effect of the MedDiet came in 1970 from the Seven Countries Study. It was first described and studied by Ancel Keys, as he observed that certain populations dwelling around the Mediterranean Sea had some special dietary habits. It had been hypothesized that these dietary habits may have a favorable effect on CVD mortality observed at variance with Northern Europe and the United States [92]. Over the past decades, the MedDiet has been the most studied dietary pattern, and the definition originally introduced by Keys has been evolved [93]. For a long now, there has been a substantial body of evidence, which has established the health benefits associated with the adherence to the MedDiet, mainly about metabolic syndrome, type 2 diabetes (T2D), CVD, and some neurodegenerative diseases and cancers [94, 95]. Regarding the BP effect of the MedDiet, several studies have found that consuming foods typical of the MedDiet might reduce the risk of hypertension. In contrast, foods not typical of this dietary pattern, such as red and processed meat, have an opposite effect on BP levels [96].

The PREvención con Dieta MEDiterránea (PREDIMED) study, was designed to assess the influence of the MedDiet on primary CVD prevention. A landmark study conducted on nearly 7500 participants at high cardiovascular risk. It investigated the effects of two MedDiets, the one supplemented with extra-virgin olive oil and the other supplemented with mixed nuts, compared to the control diet, a low-fat diet. Participants were not subjected to any caloric...
or sodium restriction. All groups received dietary counseling (including group sessions specific for each intervention group) to increase adherence to the assigned diet. At the same time, participants in the two intervention groups were also given supplementary foods, either extra-virgin olive oil or mixed nuts, to ensure high consumption of these key elements. The results over a median follow-up period of 3.8 years showed that compared to the low-fat diet, greater reductions in DBP were seen for both MedDiets [–1.5 (95% CI: –2.9 to –0.0) mmHg and –0.7 (95% CI: –1.3 to –0.1) mmHg, respectively] [97]. Nissensohn et al. [99] found that compared to the low-fat diet, the MedDiet reduced DBP [–0.7 (95% CI: –1.3 to –0.1) mmHg], but not SBP [–1.5 (95% CI: –2.9 to 0.0) mmHg] [99]. In two other meta-analyses, the MedDiet was compared to the usual or another diet (low-fat or prudent) using the results of a limited number of studies, and no separate analyses according to the type of the comparator were conducted [80,81]. Ndanuko et al. [80] found that the MedDiet reduced both SBP and DBP [–3.0 (95% CI: –3.5 to –2.6) and –1.9 (95% CI: –2.3 to –1.7) mmHg, respectively] [80], while Gay et al. [81] found that compared to the usual or another diet the MedDiet reduced DBP [–1.5 (95% CI: –2.1 to –0.8) mmHg], but not SBP [–1.2 (95% CI: –2.8 to 0.5) mmHg] [81].

Rees et al. [100] conducted two separate comparisons about the effect of the MedDiet intervention against no/minimal intervention or another dietary intervention on CVD risk factors and CVD mortality in people with or without CVD. In studies concerning the primary prevention of CVD, the MedDiet reduced both SBP and DBP when compared to no/minimal intervention [–2.9 (95% CI: –3.5 to –2.5) and –2.0 (95% CI: –2.3 to –1.7) mmHg, respectively], but when compared to another dietary intervention, the MedDiet resulted in no significant SBP or DBP reduction [–1.5 (95% CI: –3.9 to 0.9) and –0.2 (95% CI: –1.3 to 0.1) mmHg, respectively] [100]. A more recent meta-analysis conducted by Cowell et al. [101] included a larger number of RCTs. It showed that compared to the habitual or the low-fat or another diet, the MedDiet reduced SBP by –1.4 (95% CI: –2.4 to –0.4) mmHg and DBP by –1.5 (95% CI: –2.7 to –0.3) mmHg. At the same time, subgroup anal-

Table 3. Effect of the MedDiet on BP: Results from published meta-analyses of RCTs examining the effect of the MedDiet on SBP and DBP in adults.

| Author, year | Studies, n | Participants, n | Duration of trials | BP difference (mmHg) | SBP | DBP |
|-------------|-----------|----------------|-------------------|---------------------|-----|-----|
|             |           |                | Range             |                     | SBP | DBP |
|             |           |                |                   | Mean (95% CI)       | Mean (95% CI) |
| Nordmann, et al., 2011 [99] | 6          | 2650           | 2–4 years         | –1.7 (–3.3; –0.1)   | Versus low-fat diet |
| Nissensohn, et al., 2016 [99] | 6          | 7987           | 2–4 years         | –1.5 (–2.9; 0.0)    | Versus low-fat diet |
| Ndanuko, et al., 2016 [80]  | 3          | 535            | 1–2 years         | –3.0 (–3.5; –2.6)   | Versus usual/low-fat/prudent diet |
| Gay, et al., 2016 [81]      | 4          | 7703           | 2–4 years         | –1.2 (–2.8; 0.5)    | Versus usual/low-fat/prudent diet |
| Rees, et al., 2019 [100]    | Versus no/minimal intervention 2 | 269 | 3–24 months | –2.9 (–3.5; –2.5) | Versus no/minimal intervention |
|                           | Versus another dietary intervention 4 | 448 | 3–12 months | –1.5 (–3.9; 0.9) | Versus another dietary intervention |
| Cowell, et al., 2021 [101]  | 19         | 4137           | 1.5 week–5 years | –1.4 (–2.4; –0.4)  | Versus habitual/low-fat/other diet |
| Filippou, et al., 2021 [12] | 35         | 13,943         | 6 weeks–3.7 years | –1.5 (–2.8; –0.1)  | Versus usual diet/dietary intervention |
|                           |           |                |                   | –0.9 (–1.5; –0.3)  | Versus usual diet |
|                           |           |                |                   | –1.6 (–2.6; –0.6)  | Versus other dietary interventions |
|                           |           |                |                   | –0.6 (–1.3; 0.1)   | Versus other dietary interventions |
|                           |           |                |                   | –0.7 (–1.5; 0.0)   | Versus low-fat diet |

BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; RCT, randomized controlled trial; SBP, systolic blood pressure.
analysis revealed no influence of the type of the comparator diet on the BP effect of the MedDiet.

These meta-analyses provided mixed results regarding the effect of the MedDiet on BP reduction. Moreover, BP estimates were evaluated as the difference from baseline levels in each arm, introducing outcome-related bias. At variance with previous evidence, in the meta-analysis conducted recently by our group, we aimed to address the issues mentioned above and estimate the effect of the MedDiet compared to the usual diet or another dietary intervention on the attained BP reduction during follow-up [12]. The results showed that compared to all other diets (usual diet/other dietary intervention), the MedDiet reduced SBP by –1.5 (95% CI: –2.8 to –0.1) mmHg and DBP by –0.9 (95% CI: –1.5 to –0.3) mmHg. Compared only to the usual diet, the MedDiet reduced SBP and DBP [–3.1 (95% CI: –4.8 to –1.3) and –1.6 (95% CI: –2.6 to –0.6) mmHg, respectively], while compared to all other active intervention diets or only to the low-fat diet the MedDiet did not reduce SBP and DBP, meaning that it proved equally effective to reduce BP as the low-fat and all other dietary interventions taken together (e.g., prudent, hypolipidemic, low- or high-carbohydrate diet). We were unable to compare the BP effect of the MedDiet between hypertensive and non-hypertensive patients since the majority of studies were conducted in mixed populations. However, in a limited number of studies conducted in normotensive individuals, the BP effect of the MedDiet was not significant [12].

The influence of sodium intake on BP in the context of the MedDiet remains undetermined. The MedDiet was not “invented” for BP-lowering purposes, like the DASH diet, and the effects of its adoption on BP were examined along with the effects on the other CVD risk factors, such as overweight/obesity, raised blood glucose and, abnormal blood lipids, because of the evidence indicating its association with lower CVD mortality. Accordingly, the RCTs examining the BP effects of the MedDiet usually were performed without a parallel salt reduction strategy. Although MedDiet does not impose a certain level of sodium intake, it promotes the consumption of foods that are naturally low in sodium, like fruits and vegetables. Thus, individuals with higher adherence to the MedDiet have a lower salt intake. A reduction in sodium intake usually follows the adoption of the MedDiet in dietary interventions [102]. However, based on the results of the existing RCTs, it is not possible to determine whether salt reduction contributes towards the BP-lowering effects of the MedDiet. Unlike some trials that examined the DASH diet in combination with sodium restriction, there is a lack of a similar effort in MedDiet trials since they do not give sufficient data regarding the change in sodium intake. Nevertheless, it may be hypothesized that the MedDiet exerts beneficial effects towards hypertension risk because of its overall better micro-, macro-nutrient, and mineral content, which seems to decrease the level of oxidation and inflammation and reduce the exposure to harmful components of the diet, including salt [103].

6. Conclusions

Hypertension increases the risk for adverse cardiovascular and renal outcomes. However, it should be pointed out that premature morbidity and mortality begin to increase among persons whose SBP/DBP is above 115/75 mmHg. Therefore, although BP-lowering by drugs should be reserved for patients with hypertension or high cardiovascular risk and high normal BP, non-pharmacological measures, including appropriate dietary and lifestyle changes, should be implemented to all individuals irrespectively of BP levels. In overweight and obese hypertensive patients, a core recommendation is weight reduction through reduced energy intake and increased physical activity to reduce fat storage and ectopic lipid deposition in key target organs of BP control. Such measures, in general, may increase the net clinical benefit, contribute to BP control with fewer antihypertensive drugs, and exert properties independent of BP reduction, decreasing CVD risk more than expected.

Regarding the dietary strategies, they reduce sodium intake and promote a healthful dietary pattern, such as the DASH diet or the MedDiet, which influence various physiological mechanisms controlling BP and have beneficial effects on BP levels and overall cardiovascular health. Salt intake levels should be reduced progressively to accomplish a modest, long-term salt reduction, rather than an extreme and sudden fall in dietary consumption of salt. In the context of the DASH diet, salt restriction produces a less pronounced reduction in BP, which could be because of the overlapping mechanisms of action, resulting in a reduced capacity to lower BP with salt reduction further, when accounting for the effects of the DASH diet. Evidence about the contribution of salt reduction in the context of the MedDiet is yet insufficient.

Abbreviations

BP, blood pressure; CVD, cardiovascular disease; CDK, chronic kidney disease; DASH, dietary approaches to stop hypertension; DBP, diastolic blood pressure; MedDiet, Mediterranean diet; RCT, randomized controlled trial; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure; SNS, sympathetic nervous system.

Author contributions

CF, FT, and DP designed the paper; CF, FT and CT performed the literature search; CF, FT and CT wrote the paper; DP, EM, PN, DT, and KT assisted in the revision of the manuscript; CF, FT, DP, EM, CT, PN, DT, and KT had primary responsibility for final content.

Ethics approval and consent to participate

Not applicable.
Acknowledgment
We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.

Funding
This research was funded by the Institute of Study, Research, Education and, Treatment of Vascular, Heart, Brain and, Kidney Diseases (INAKEN), grant number 1023.8 USD.

Conflict of interest
The authors declare no conflict of interest.

References
[1] Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology. 2020; 76: 2982–3021.
[2] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398: 957–980.
[3] Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nature Reviews Cardiology. 2021; 18: 785–802.
[4] Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk—overview and meta-analyses of randomized trials. Journal of Hypertension. 2014; 32: 2305–2314.
[5] Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of Hypertension. Circulation Research. 2021; 128: 847–863.
[6] Montani J, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. International Journal of Obesity and Related Metabolic Disorders. 2004; 28: S58–S65.
[7] Lackland DT, Egan BM. Dietary salt restriction and blood pressure in clinical trials. Current Hypertension Reports. 2007; 9: 314–319.
[8] He FJ, Tan M, Ma Y, MacGregor GA. Salt Reduction to Prevent Hypertension and Cardiovascular Disease. Journal of the American College of Cardiology. 2020; 75: 632–647.
[9] Fu J, Liu Y, Zhang L, Zhou L, Li D, Quan H, et al. Nonpharmacologic Interventions for Reducing Blood Pressure in Adults with Prehypertension to Established Hypertension. Journal of the American Heart Association. 2020; 9: e016804.
[10] Strilchuk L, Cincione RI, Fogacci F, Cicero AFG. Dietary interventions in blood pressure lowering: current evidence in 2020. Kardiol Pol. 2020; 78: 659–666.
[11] Filipoupol CD, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimtriadis KS, Sotropoulou LI, et al. Dietary Approaches to Stop Hypertension: a systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition. 2021; 40: 3191–3200.
[12] Biggiani A. Salt Taste, Nutrition, and Health. Nutrients. 2020; 12: 1537.
[13] Lupoli S, Salvi E, Barlassina C. Dietary Salt Intake, Blood Pressure, and Genes. Current Nutrition Reports. 2013; 2: 134–141.
[14] Biggiani A. Salt: mechanisms of sodium balance: total body sodium, surrogate variables, and renal sodium excretion. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2018; 315: R945–R962.
[15] McCellum L, Lip S, Padmanabhan S. The hidden hand of chlorine in hypertension. Pflugers Archi. 2015; 467: 595–603.
[16] Rust P, Ekemecioglu C. Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension. Advances in Experimental Medicine and Biology. 2017; 956: 61–84.
[17] Eaton SB, Eaton SB. Paleolithic vs. modern diets—selected pathophysiological implications. European Journal of Nutrition. 2000; 39: 67–70.
[18] Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. The New England Journal of Medicine. 2007; 356: 1966–1978.
[19] Michell AR. Physiological aspects of the requirement for sodium in mammals. Nutrition Research Reviews. 2009; 2: 149–160.
[20] Ha SK. Dietary salt intake and hypertension. Electrolyte &Amp; Blood Pressure. 2014; 12: 7–18.
[21] Garfinkle MA. Salt and essential hypertension: pathophysiology and implications for treatment. Journal of the American Society of Hypertension. 2017; 11: 385–391.
[22] Saxena T, Ali AO, Saxena M. Pathophysiology of essential hypertension: an update. Expert Review of Cardiovascular Therapy. 2018; 16: 879–887.
[23] de Wardener HE, He FJ, MacGregor GA. Plasma sodium and hypertension. Kidney International. 2004; 66: 2454–2466.
[24] Schweda F. Salt feedback on the renin-angiotensin-aldosterone system. Pflugers Archi. 2015; 467: 565–576.
[25] Stocker SD, Madden CJ, Sved AF. Excess dietary salt intake alters the excitability of central sympathetic networks. Physiology &Amp; Behavior. 2010; 100: 519–524.
[26] Oberleithner H, Riethmüller C, Schillers H, MacGregor GA, de Wardener HE. Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 16281–16286.
[27] Schiffrin EL. How Structure, Mechanics, and Function of the Vasculature Contribute to Blood Pressure Elevation in Hypertension. Canadian Journal of Cardiology. 2020; 36: 648–658.
[28] Titze J. A different view on sodium balance. Current Opinion in Nephrology and Hypertension. 2015; 24: 14–20.
[29] Sterns RH. Disorders of plasma sodium–causes, consequences, and correction. The New England Journal of Medicine. 2015; 372: 55–65.
[30] Grillo A, Salvi L, Coruzzi P, Salvi P, Parati G. Sodium Intake and Hypertension. Nutrients. 2019; 11: 1970.
[31] Guyton AC, Coleman TG, Cowley AV, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation, and in hypertension. The American Journal of Medicine. 1972; 52: 584–594.
[32] Guyton AC. The surprising kidney-fluid mechanism for pressure control—its infinite gain! Hypertension. 1990; 16: 725–730.
[33] Hall JE, Guyton AC, Coleman TG, Mizelle HL, Woods LL. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Federation Proceedings. 1986; 45: 2897–2903.
[34] Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. The Journal of Physiology. 2014; 592: 3955–3967.
Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. The American Journal of Clinical Nutrition. 1997; 65: 612S–617S.

Eltijovich F, Weinberger MH, Anderson CM, Appel LJ, Bursztyn M, Cook NR, et al. Salt Sensitivity of Blood Pressure. Hypertension. 2016; 68: e62.

Strazzullo P, Siani A, Russo P. Salt-sensitivity of blood pressure: a paradigm of gene-environment interaction. Italian Heart Journal. 2000; 1: S15–S19.

Hirohama D, Fujita T. Evaluation of the pathophysiological mechanisms of salt-sensitive hypertension. Hypertension Research. 2019; 42: 1848–1857.

Choi HY, Park HC, Ha SK. Salt Sensitivity and Hypertension: a Paradigm Shift from Kidney Malfunction to Vascular Endothelial Dysfunction. Electrolyte &amp; Blood Pressure. 2015; 13: 7–16.

Hall JE, Guyton AC, Brands MW. Pressure-volume regulation in hypertension. Kidney International. Supplement. 1996; 55: S35–S41.

Kawarazaki W, Fujita T. Kidney and epigenetic mechanisms of salt-sensitive hypertension. Nature Reviews Nephrology. 2021; 17: 350–363.

Balafa O, Kalaitzidis RG. Salt sensitivity and hypertension. Journal of Human Hypertension. 2021; 35: 184–192.

Hall JE, Mizelle HL, Hildebrandt DA, Brands MW. Abnormal pressure natriuresis: a cause or a consequence of hypertension? Hypertension. 1990; 15: 547–559.

World Health Organization. Guideline: Sodium intake for adults and children. World Health Organization: Geneva. 2012.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39: 3021–3104.

Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/ABC/ACPM/AGS/AHA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71: 2199–2269.

Ambard L, Beaujard E. Causes of arterial hypertension. Archives of General Internal Medicine. 1904; 1: 520–533. (In French)

Allen FM, Sherrill JW. The treatment of arterial hypertension. The Journal of Metabolic Research. 1922; 2: 429–545.

Kempen W. Treatment of hypertensive vascular disease with a rice diet. The American Journal of Medicine. 1948; 4: 545–577.

MacGregor GA, Markandu ND, Best FE, Elder DM, Cam JM, Sagnella GA, et al. Double-blind randomised crossover trial of moderate sodium restriction in essential hypertension. Lancet. 1982; 1: 351–355.

Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. Journal of the American Medical Association. 1996; 275: 1590–1597.

Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. The American Journal of Clinical Nutrition. 1997; 65: 643S–651S.

Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. British Medical Journal. 2002; 325: 628.

Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a meta-regression analysis of randomized trials. Journal of Human Hypertension. 2003; 17: 471–480.

Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. British Medical Journal. 2013; 346: f3126.

He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomized trials. British Medical Journal. 2013; 346: f3125.

Graudal NA, Hubeck-Graudal T, Junges G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. The Cochrane database of systematic reviews. 2020; 12: CD004022.

Huang L, Trieu K, Yoshihara S, Neal B, Woodward M, Campbell NRC, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. British Medical Journal. 2020; 368: m315.

Filippini T, Malavolti M, Whelton PK, Naska A, Orsini N, Vinceti M. Blood Pressure Effects of Sodium Reduction. Circulation. 2021; 143: 1542–1567.

Graudal N, Hubeck-Graudal T, Junges G, McCarron DA. The Significance of Duration and Amount of Sodium Reduction Intervention in Normotensive and Hypertensive Individuals: a Meta-Analysis. Advances in Nutrition. 2015; 6: 169–177.

Graudal NA, Hubeck-Graudal T, Junges G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. The Cochrane Database of Systematic Reviews. 2017; 4: CD004022.

Craddock SR, Elmer PJ, Obarzanek E, Vollmer WM, Svetkey LP, Swain MC. The DASH diet and blood pressure. Current Atherosclerosis Reports. 2003; 5: 484–491.

Karanja NM, Obarzanek e, LIN P, McCullough ML, Phillips KM, Swain JF, et al. Descriptive Characteristics of the Dietary Patterns used in the Dietary Approaches to Stop Hypertension Trial. Journal of the American Dietetic Association. 1999; 99: S19–S27.

Sukhato K, Akksilp K, Dellow A, Vathesatogkit P, Anthaisintawee T. Efficacy of different dietary patterns on lowering of blood pressure level: an umbrella review. The American Journal of Clinical Nutrition. 2020; 112: 1584–1598.

Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovás JM, Ruilope LM, et al. Lifestyle interventions for the prevention and treatment of hypertension. Nature Reviews Cardiology. 2021; 18: 251–275.

Maris SA, Williams JS, Sun B, Brown S, Mitchell GF, Conlin PR. Interactions of the DASH Diet with the Renin-Angiotensin- Aldosterone System. Current Developments in Nutrition. 2019; 3: nzx091.

Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G. Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on the Pressure-Natriuresis Relationship. Hypertension. 2003; 42: 8–13.

Staruschenko A. Beneficial Effects of High Potassium: Contribution of Renal Basolateral K+ Channels. Hypertension. 2018; 71: 1015–1022.

Villa-Etchegoyen C, Lombarte M, Matamoros N, Belizán JM, Cormick G. Mechanisms Involved in the Relationship between Low Calcium Intake and High Blood Pressure. Nutrients. 2019; 11: 1112.

Juraschek SP, Kovel LC, Appel LJ, Miller ER, Sacks FM, Chang AR, et al. Effects of Diet and Sodium Reduction on Cardiac Injury, Strain, and Inflammation. Journal of the American College of Cardiology. 2021; 77: 2625–2634.

Jackson JK, Patterson AJ, MacDonald-Wicks LK, Oldmeadow
Nguyen HT, Bertoni AG, Nettleton JA, Bluemke DA, Leftan E, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Cowell OR, Mistry N, Deighton K, Matu J, Griffiths A, Mini-Lari A, Sohouli MH, Fatahi S, Cerqueira HS, Santos HO, Pour-Keys A. Coronary heart disease in seven countries. Summary. Saneei P, Salehi-Abargouei A, Esmaillzadeh A, Azadbakht L. Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Merino J, Guasch-Ferré M, Martínez-González MA, Corella. Mediterranean dietary pattern, Willett WC, Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced sodium dietary and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. The New England Journal of Medicine. 2001; 344: 3–10.

Juraschek SP, Miller ER, Weaver CM, Appel LJ. Effects of Sodium Reduction and the DASH Diet in Relation to Baseline Blood Pressure. Journal of the American College of Cardiology. 2017; 70: 2841–2848.

Sanei P, Salehi-Abargouei A, Esmailizadeh A, Azadbakht L. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials. Nutrition, Metabolism, and Cardiovascular Diseases. 2014; 24: 1253–1261.

Sierro M, Lara J, Chowdhury S, Ashor A, Ogugi C, Mathers JC. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. The British Journal of Nutrition. 2015; 113: 1–15.

Ndanuko RN, Tapsell LC, Charlton KE, Neale EP, Batterham MJ. Dietary Patterns and Blood Pressure in Adults: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition. 2016; 7: 76–89.

Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2016; 67: 733–739.

Lari A, Sohouli MH, Fatári S, Carruega HS, Santos HO, Pourrajab B, et al. The effects of the Dietary Approaches to Stop Hypertension (DASH) diet on metabolic risk factors in patients with chronic disease: a systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases. 2021; 31: 2766–2778.

Bach-Faiq A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Demiris S, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutrition. 2011; 14: 2274–2284.

Willet WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, et al. Mediterranean diet pyramid: a cultural model for healthy eating. The American Journal of Clinical Nutrition. 1995; 61: I186–I195.

Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. Nutrition, Metabolism, and Cardiovascular Diseases. 2014; 24: 929–939.

De Pergola G, D’Alessandro A. Influence of Mediterranean Diet on Blood Pressure. Nutrients. 2018; 10: 1700.

Medina-Román A, Estruch R, Tresserra-Rimbau A, Vallverdú-Queralt A, Lamuela-Raventos RM. The effect of polyphenol consumption on blood pressure. Mini Reviews in Medicinal Chemistry. 2013; 13: 1137–1149.

Zheng J, Zhou Y, Li S, Zhang P, Zhou T, Xu D, et al. Effects and Mechanisms of Fruit and Vegetable Juices on Cardiovascular Diseases. International Journal of Molecular Sciences. 2017; 18: 555.

Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, et al. Whole grain cereals for the primary or secondary prevention of cardiovascular disease. The Cochrane Database of Systematic Reviews. 2017; 8: CD005051.

Chiva-Blanch G, Arranz S, Lamuela-Raventos RM, Estruch R. Effects of wine, alcohol and polyphenols on cardiovascular disease risk factors: evidences from human studies. Alcohol and Alcoholism. 2013; 48: 270–277.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42: 3227–3337.

Keys A. Coronary heart disease in seven countries. Summary. Circulation. 1970; 41: 1186–1195.

Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediterranean Diet; a Literature Review. Nutrients. 2015; 7: 9139–9153.

Soifi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. British Medical Journal. 2008; 337: a1344.

Dinu M, Pagliari G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. European Journal of Clinical Nutrition. 2018; 72: 30–43.

Ozeneck C, Laddu DR, Arena R, Lavie CJ. The role of diet for prevention and management of hypertension. Current Opinion in Cardiology. 2018; 33: 388–393.

Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of the Mediterranean diet on blood pressure in the PREMIDEM trial: results from a randomized controlled trial. BMC Medicine. 2013; 11: 207.

Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, et al. Meta-Analysis Comparing Mediterranean to Low-Fat Diets for Modification of Cardiovascular Risk Factors. The American Journal of Medicine. 2011; 124: 841–851.e2.

Nissensohn M, Román-Viñas B, Sánchez-Villegas A, Piscopo S, Serra-Majem L. The Effect of the Mediterranean Diet on Hypertension: a Systematic Review and Meta-Analysis. Journal of Nutrition Education and Behavior. 2016; 48: 42–53.e1.

Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2019; 3: CD009825.

Cowell OR, Mistry N, Deighton K, Matu J, Griffiths A, Minihane AM, et al. Effects of a Mediterranean diet on blood pressure: a systematic review and meta-analysis of randomized controlled trials and observational studies. Journal of Hypertension. 2021; 39: 729–739.

Merino J, Guasch-Ferré M, Martínez-González MA, Corella D, Estruch R, Fito M, et al. Is complying with the recommendations of sodium intake beneficial for health in individuals at high cardiovascular risk? Findings from the PREMIDEM study. The American Journal of Clinical Nutrition. 2015; 101: 440–448.

La Verde M, Mulé S, Zappalà G, Privitera G, Maugeri G, Pecora F, et al. Higher adherence to the Mediterranean diet is inversely associated with having hypertension: is low salt intake a mediating factor? International Journal of Food Sciences and Nutrition. 2018; 69: 235–244.